220193-71-5

Upstream product

• 2466-76-4 N-Acetylimidazole 
• 220193-60-2 {4-[2-{1-[2-carbamoyl-1-(3-naphthalen-1-yl-propylcarbamoyl)-ethylcarbamoyl]-cyclohexylcarbamoyl}-2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethyl]-benzyl}-phosphonic acid di-tert-butyl ester 
• 220193-51-1 {1-[2-carbamoyl-1-(3-naphthalen-1-yl-propylcarbamoyl)-ethylcarbamoyl]-cyclohexyl}-carbamic acid tert-butyl ester 
• 220193-52-2 (2S)-2-amino-N₁-[3-(1-naphthalenyl)propyl]butanediamide 
• 350584-51-9 (4-{(S)-2-Acetylamino-2-[1-((S)-2-carbamoyl-1-prop-2-ynylcarbamoyl-ethylcarbamoyl)-cyclohexylcarbamoyl]-ethyl}-benzyl)-phosphonic acid di-tert-butyl ester 
• 350584-50-8 2-amino-N¹-prop-2-ynyl-succinamide 
• 221303-31-7 1-[(S)-2-Acetylamino-3-(4-chloromethyl-phenyl)-propionylamino]-cyclohexanecarboxylic acid methyl ester 
• 13086-84-5 di-tert-butyl phosphite 
• 90-14-2 1-Iodonaphthalene 

Relevant academic research and scientific papers

Convergent synthesis of potent peptide inhibitors of the Grb2-SH2 domain by palladium catalyzed coupling of a terminal alkyne

A new strategy was developed to prepare in a very efficient and convergent manner C-terminal modified tripeptides with high affinities for the Grb2-SH2 domain. Using Pd(PPh3)2Cl2 as catalyst, selected naphthyl iodides and

Potent inhibition of Grb2 SH2 domain binding by non-phosphate- containing ligands

Development of Grb2 Src homology 2 (SH2) domain binding inhibitors has important implications for treatment of a variety of diseases, including several cancers. In cellular studies, inhibitors of Grb2 SH2 domain binding have to date been large, highly cha